Natural Products and Metabolites

Yazaki, Kazufumi

doi:10.1002/0470869143.kc039

Cited by 13 publications

(14 citation statements)

References 346 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Along with conventional plant cell culture systems involved in the production of compounds like shikonin, natural compounds may be produced by metabolic engineering. For example, foreign genes can be introduced into various host plants, or expressed in microorganisms (Yazaki 2004). Although the production of these secondary metabolites requires basic knowledge of their biosynthetic pathways, the pathways involved in the biosynthetic reactions of certain secondary metabolites have not been completely elucidated.…”

Section: Future Aspectsmentioning

confidence: 99%

<i>Lithospermum erythrorhizon</i> cell cultures: Present and future aspects

Yazaki

2017

Plant Biotechnology

Self Cite

View full text Add to dashboard Cite

Lithospermum erythrorhizon cell cultures have been used to produce plant secondary metabolites, as well as in biosynthetic studies. Shikonin, a representative secondary metabolite of L. erythrorhizon, was first produced industrially by dedifferentiated cell cultures in the 1980s. This culture system has since been used in research on various plant secondary metabolites. Other boraginaceaeous plant species, including Arnebia, Echium, Onosma and Alkanna, have been shown to produce shikonin, and studies have assessed shikonin regulation, including transgene expression, in these plants. This review summarizes current knowledge of shikonin production by L. erythrorhizon cell and hairy root cultures, including the historical aspect of large-scale production, and discusses future biochemical and biological research using this species.

show abstract

Section: Future Aspectsmentioning

confidence: 99%

<i>Lithospermum erythrorhizon</i> cell cultures: Present and future aspects

Yazaki

2017

Plant Biotechnology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Molecular breeding to establish new plant resources that accumulate high amounts of desired pharmaceuticals is an effective approach to solve the current problems (Yazaki 2004). In general, however, the establishment of a reasonable transformation method is a big hurdle, in particular, for such plant species that produce valuable secondary metabolites.…”

mentioning

confidence: 99%

Establishment of Rhizobium-mediated transformation of Coptis japonica and molecular analyses of transgenic plants

Shitan

Kiuchi

Sato

et al. 2005

Plant Biotechnology

Self Cite

View full text Add to dashboard Cite

Coptis japonica is a perennial medicinal plant grown in Asia, and its rhizome is used as crude drug, in which berberine is highly accumulated as the main alkaloid. In this study, a transformation method for C. japonica using Rhizobium has been established. Young petioles were infected with Rhizobium radiobactor Gv3101 (pMP90) harboring a plasmid with b-glucuronidase (gus) driven by cauliflower mosaic virus 35S promoter and hygromycin phosphotransferase (hpt) gene as the selection marker. GUS assay showed that 46% of the calli grown on hygromycin plates clearly expressed the gus gene. As an application of the transformation method, an endogenous cDNA encoding an ABC protein, CjMDR1, which is involved in berberine transport, was introduced in sense orientation. Cjmdr1 transgenic plant (Sense-2) regenerated from hygromycin resistant callus line had a single copy of integrated hpt gene in its genomic DNA. Northern analyses of the Sense-2 plant showed that Cjmdr1 mRNA levels were lower in all organs examined than those of wild-type plant, which suggested that co-suppression of Cjmdr1 expression occurred. Indeed, the berberine content in Sense-2 was also suppressed. This is the first report of stable transformation of Coptis spp. and also of the alteration of a secondary metabolite by transport engineering.

show abstract

“…The first recombinant protein made by cultured tobacco suspension cells was human serum albumin (HSA) (Sijmons et al 1990). To date, 20 different recombinant proteins have been successfully produced in proof-of-principle studies with plant cell cultures (Hellwig et al 2004;Hülsing 2005;Kreis et al 2001;Marshall 2006;Yazaki 2004;Vanisree et al 2004;Voedisch et al 2005). An updated summary of such PMPs (plant-made pharmaceuticals = protein-based medicines produced in transgenic plants and plant cells) is given in http://www.molecularfarming.…”

Section: Application Examples and Potential Active Agent Candidatesmentioning

confidence: 99%

“…Taxol is the generic name for the active ingredient of paclitaxel, an anti-cancer (ovarian, breast, and small-cell lung cancer) drug stopping cell division while stabilizing microtubule complexes (Wink et al 2005). Cultivation of yew suspension cells in 70 m 3 stirred bioreactors (Phyton Biotech, Germany) ensured paclitaxel amounts exceeded those in intact plants, which constitute 0.01% of dry weight (Yazaki 2004). Further potential anticancer candidates being studied intensively in respect of their suitability for plant cell-based bioprocessing are camptothecin, podophyllotoxin, vincristine, vinblastine, and colchinine (Wink et al 2005).…”

Section: Application Examples and Potential Active Agent Candidatesmentioning

confidence: 99%

Plant Cell-Based Bioprocessing

Eibl

2009

Cell and Tissue Reaction Engineering

View full text Add to dashboard Cite

Plant cell-based bioprocessing is the use of plant cell and tissue cultures for the production of biologically active substances (low molecular secondary metabolites and recombinant proteins). The most significant advantage of plant cell culture over the traditionally grown whole wild plant or engineered transgenic plant is the sterile production of metabolites under defined controlled conditions independent of climatic changes and soil conditions, which means that variations in product yield and quality can be better avoided. Furthermore, regulatory requirements such as the cGMP standards, which have to be adhered to in the early stages of pharmaceutical production, are more easily met.Moreover, plant cells are capable of performing complex posttranslational processing, which is a precondition for heterologous protein expression. When compared with mammalian cells, which currently dominate in the commercial protein manufacture, plant cell cultures as alternative expression systems guarantee safer processes because there is a lower risk of contamination by mammalian viruses, pathogens, and toxins. In addition to this considerable advantage, the process costs can also be substantially reduced. This is due to the fact that plant cell culture medium is very simple in composition and therefore relatively inexpensive.This chapter provides an overview of culture types, techniques, and suitable bioreactors used to produce secondary metabolites and recombinant proteins in plant cells. We describe plant cell culture basics, discuss key topics relevant to plant cell bioreactor engineering with application examples, and give an overview of approaches to improving productivity of plant cell-based processes.

show abstract

Natural Products and Metabolites

Cited by 13 publications

References 346 publications

<i>Lithospermum erythrorhizon</i> cell cultures: Present and future aspects

<i>Lithospermum erythrorhizon</i> cell cultures: Present and future aspects

Establishment of Rhizobium-mediated transformation of Coptis japonica and molecular analyses of transgenic plants

Plant Cell-Based Bioprocessing

Contact Info

Product

Resources

About